Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Entrada Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 56 | 55 | −1 |
| Shares | 25.8M | 26.0M | +283.8K (+1.1%) |
| Value | $389.9M | $411.4M | +$21.5M (+5.5%) |
New holders (4)
Institutions that held Entrada Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cornercap Investment Counsel Inc | 13,977 | $220.8K | 0.04% |
| State of Wisconsin Investment Board | 10,023 | $158.4K | 0.00% |
| SG Americas Securities, LLC | 9,174 | $145.0K | 0.00% |
| Allspring Global Investments Holdings, LLC | 2,798 | $44.2K | 0.00% |
Sold out (5)
Institutions that held Entrada Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Millennium Management LLC | 18,298 | $277.0K |
| Man Group plc | 14,466 | $219.0K |
| Marshall Wace, LLP | 11,312 | $171.3K |
| Lazard Asset Management LLC | 2,417 | $36.0K |
| The PNC Financial Services Group, Inc. | 200 | $3.03K |